BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
The use of cannabis for Hyperemesis Gravidarum (HG).
Authors: Gideon Koren, Rana Cohen
Journal of Cannabis Research, 30 January 2020
—
Background: Hyperemesis Gravidarum (HG) responds only partially to standard antiemetic medications. Cannabis has been known to possess antiemetic effects and there are several medicinal cannabinoids used as anti -emetics for cancer chemotherapy. Its favorable use for HG has be…
Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation.
Authors: Veronica Stahl, Kumar Vasudevan
Cureus, 29 January 2020
—
Background Dental plaque is a complex biofilm that gets formed on the teeth and acts as a reservoir of different microbes. It is the root cause for the occurrence of several dental problems and diseases, including cavities, bad breath, bleeding gums, tooth decay, and tooth los…
The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage
A long-term observational study found cannabis worked as an alternative to prescription opioids in over half of patients with low back pain and an be an adjunct therapy to diminish chronic opioid use for some people.
Report from House of Representatives Hearing “Cannabis Policy – For The New Decade”
Dr. Patricia Frye summarizes a cannabis policy hearing at the House of Representatives. Dr. Frye saw strong bipartisan support for decreasing the barriers to research on cannabis medicine.
Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
Authors: Chao Liu, Sayed H. Sadat, Koji Ebisumoto, Akihiro Sakai, Bharat A. Panuganti, Shuling Ren, et al
Clinical Cancer Research, 13 January 2020
—
PURPOSE: Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is associated with daily marijuana use and is also increasing in parallel with increased marijuana use in the United States. Our study is designed to define the interaction between cannab…
Update on the Vape Pen Crisis: Considerations for Healthcare Professionals
The SCC sent a poll to its membership to gauge how those within the organization were approaching the vape pen issue and EVALI. Learn more about their recommendations and considerations.
Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement.
Authors: B. Whitcomb, C. Lutman, M. Pearl, E. Medlin, E. Prendergast, K. Robison, W. Burke
Gynecologic Oncology, 10 January 2020
—
Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system. Cannabinoids reduce chemotherapy induced nausea or vomiting (CINV) and neuropathic pain. Each state has its own regulations for medical and recreational cannabis use. Ef…
Medical students are unprepared to counsel patients about medical cannabis and want to learn more.
Authors: Abraham Benavides, Nicholas Gregorio, Puneet Gupta, Mikhail Kogan
Complementary Therapies in Medicine, January 2020
—
Introduction: Over-the-counter and prescribed medical cannabis products are used by patients for various conditions including psychiatric disorders, pain management, and other neurodegenerative conditions.1 Despite this growing public interest and increasing legal availability…
Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Authors: Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo
Nature Reviews Neurology, January 2020
—
Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been marked by disappointment, es…
Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.
Authors: Javier Vázquez-Bourgon, Víctor Ortiz-García de la Foz, Irene Suarez-Pereira, et al
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20 December 2019
—
INTRODUCTION: Increased incidence of obesity and excess weight lead to an increased incidence of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates a protective effect of cannabis consumption on weight gain and related metabolic alterations in psychosis patie…
IACM 2019 Highlights: Defending Doctors’ Rights Across the Globe
The 2019 IACM conference in Berlin highlighted talks from the top professionals in the field of cannabis science. Christine Milentis reports on the history of cannabis for medical use and the rights of doctors across the globe to prescribe it.
Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey.
A study published in BMC Family Practice sought to characterize the clinical practice characteristics of medical professionals who recommend cannabis.